Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E CD274 pos |
Therapy | Binimetinib + Encorafenib + Nivolumab + Temozolomide |
Indication/Tumor Type | glioblastoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E CD274 pos | glioblastoma | predicted - sensitive | Binimetinib + Encorafenib + Nivolumab + Temozolomide | Case Reports/Case Series | Actionable | In a clinical case study, the addition of Mektovi (binimetinib) and Braftovi (encorafenib) to treatment with the combination of Opdivo (nivolumab) and Temodar (temozolomide) resulted in a complete response after 6 months in a patient with CD274 (PD-L1), PDCD1 (PD-1)-positive glioblastoma harboring BRAF V600E, and the patient remained progression-free for at least 20 months while on treatment (PMID: 39036436). | 39036436 |
PubMed Id | Reference Title | Details |
---|---|---|
(39036436) | Neoadjuvant combination treatment with checkpoint inhibitors, chemotherapy, and BRAF/MEK inhibitors for BRAFV600E glioblastoma results in sustained response: A case report. | Full reference... |